David K Raynor

List of Publications by Year
in descending order

72 papers	2,417 citations	257357 24 h-index	214721 47 g-index
73 all docs	73 docs citations	73 times ranked	2199 citing authors

#	Article	IF	Citations
1	Costs and Cost-Effectiveness of User-Testing of Health Professionals' Guidelines to Reduce the Frequency of Intravenous Medicines Administration Errors by Nurses in the United Kingdom: A Probabilistic Model Based on Voriconazole Administration. Applied Health Economics and Health Policy, 2022, 20, 91-104.	1.0	3
2	User Testing to Improve Retrieval and Comprehension of Information in Guidelines to Improve Medicines Safety. Journal of Patient Safety, 2022, 18, e172-e179.	0.7	6
3	Barriers and facilitators of successful deprescribing as described by older patients living with frailty, their informal carers and clinicians: a qualitative interview study. BMJ Open, 2022, 12, e054279.	0.8	12
4	User-testing guidelines to improve the safety of intravenous medicines administration: a randomised in situ simulation study. BMJ Quality and Safety, 2021, 30, 17-26.	1.8	10
5	Using experience-based co-design with patients, carers and healthcare professionals to develop theory-based interventions for safer medicines use. Research in Social and Administrative Pharmacy, 2021, 17, 2127-2135.	1.5	29
6	Developing and user testing new pharmacy label formats—A study to inform labelling standards. Health Expectations, 2021, 24, 1125-1136.	1.1	3
7	Experience-based co-design—Adapting the method for a researcher-initiated study in a multi-site setting. Health Expectations, 2020, 23, 562-570.	1.1	32
8	Comparison of International Regulations for Written Medicine Information (WMI) on Prescription Medicines. Therapeutic Innovation and Regulatory Science, 2019, 53, 215-226.	0.8	7
9	What has been the impact of the Traditional Herbal Registration (THR) scheme in the UK on information provided with herbal products bought over the counter?. BMC Complementary and Alternative Medicine, 2019, 19, 85.	3.7	3
10	Comparative User Testing of Australian and UK Over-the-Counter Labels and Leaflets for Diclofenac. Therapeutic Innovation and Regulatory Science, 2018, 52, 38-48.	0.8	6
11	Developing alternative over-the-counter medicine label formats: How do they compare when evaluated by consumers?. Research in Social and Administrative Pharmacy, 2018, 14, 248-261.	1.5	7
12	Clinical Trial Results Summary for Laypersons: A User Testing Study. Therapeutic Innovation and Regulatory Science, 2018, 52, 606-628.	0.8	9
13	Written information about individual medicines for consumers. The Cochrane Library, 2017, 2017, CD002104.	1.5	41
14	Exploring the prevalence of and factors associated with advice on prescription medicines: A survey of community pharmacies in an English city. Health and Social Care in the Community, 2017, 25, 1774-1786.	0.7	8
15	User testing as a method for identifying how consumers say they would act on information related to over-the-counter medicines. Research in Social and Administrative Pharmacy, 2017, 13, 476-484.	1.5	13
16	'It's all there in black and white' – or is it? Consumer perspectives on the proposed <scp>A</scp>ustralian <scp>M</scp>edicine <scp>I</scp>nformation <scp>B</scp>ox over-the-counter label format. Health Expectations, 2016, 19, 948-961.	1.1	12
17	Do Patients Use a Headline Section in a Leaflet to Find Key Information About Their Medicines? Findings From a User-Test Study. Therapeutic Innovation and Regulatory Science, 2016, 50, 581-591.	0.8	5
18	Exploring consumer opinions on the presentation of side-effects information in <scp>A</scp>ustralian <scp>C</scp>onsumer <scp>M</scp>edicine <scp>I</scp>nformation leaflets. Health Expectations, 2016, 19, 543-556.	1.1	14

#	ARTICLE	IF	CITATIONS
19	Consumer Opinions on Existing and Proposed Australian Over-the-Counter Medicine Labeling Strategies in Comparison With the Standardized US Drug Facts Label. Therapeutic Innovation and Regulatory Science, 2016, 50, 427-435.	0.8	6
20	Consumer interpretation of ramipril and clopidogrel medication risk information – implications for risk communication strategies. Patient Preference and Adherence, 2015, 9, 983.	0.8	7
21	How to Test Mandatory Text Templates: The European Patient Information Leaflet. PLoS ONE, 2015, 10, e0139250.	1.1	6
22	The design and user-testing of a question prompt list for attention-deficit/hyperactivity disorder. BMJ Open, 2014, 4, e006585.	0.8	17
23	The Effectiveness of the Summary of Product Characteristics (SmPC) and Recommendations for Improvement. Therapeutic Innovation and Regulatory Science, 2014, 48, 255-265.	0.8	15
24	Design and comprehensibility of over-the-counter product labels and leaflets: a narrative review. International Journal of Clinical Pharmacy, 2014, 36, 865-872.	1.0	34
25	Beyond needs and expectations: identifying the barriers and facilitators to written medicine information provision and use in Australia. Health Expectations, 2014, 17, 220-231.	1.1	34
26	Enhancing provision of written medicine information in Australia: pharmacist, general practitioner and consumer perceptions of the barriers and facilitators. BMC Health Services Research, 2014, 14, 183.	0.9	35
27	Pharmacist, general practitioner and consumer use of written medicine information in Australia: Are they on the same page?. Research in Social and Administrative Pharmacy, 2014, 10, 656-668.	1.5	33
28	Balance appointment information leaflets: Employing performance-based user-testing to improve understanding. International Journal of Audiology, 2013, 52, 162-168.	0.9	9
29	Worlds apart? An exploration of prescribing and medicine-taking decisions by patients, GPs and local policy makers. Health Policy, 2013, 112, 264-272.	1.4	6
30	User testing in developing patient medication information in Europe. Research in Social and Administrative Pharmacy, 2013, 9, 640-645.	1.5	37
31	Pharmacist and general practitioner ambivalence about providing written medicine information to patientsâ€"A qualitative study. Research in Social and Administrative Pharmacy, 2013, 9, 517-530.	1.5	20
32	European Public Assessment Report (EPAR) summaries for the public: are they fit for purpose? A user-testing study. BMJ Open, 2013, 3, e003185.	0.8	15
33	It's for your benefit: exploring patients' opinions about the inclusion of textual and numerical benefit information in medicine leaflets. International Journal of Pharmacy Practice, 2013, 21, 216-225.	0.3	19
34	The AuthorsÊ¼ Reply. Drugs and Aging, 2012, 29, 250.	1.3	0
35	The compatibility of prescribing guidelines and the doctor-patient partnership: a primary care mixed-methods study. British Journal of General Practice, 2012, 62, e275-e281.	0.7	26
36	How Do the Attitudes and Beliefs of Older People and Healthcare Professionals Impact on the Use of Multi-Compartment Compliance Aids?. Drugs and Aging, 2011, 28, 403-414.	1.3	28

#	ARTICLE	IF	CITATIONS
37	Are health professionals ready for the new philosophy of concordance in medicine taking?. International Journal of Pharmacy Practice, 2011, 9, 81-84.	0.3	29
38	Testing two methods of presenting side effect risk information about common medicines. International Journal of Pharmacy Practice, 2011, 9, 6-6.	0.3	13
39	Mind the gap: how compliance aids increase the distance between patients and their medicines. International Journal of Pharmacy Practice, 2011, 9, 46-46.	0.3	6
40	Clinical medication review by a pharmacist of patients on repeat prescriptions in general practice. International Journal of Pharmacy Practice, 2011, 9, 47-47.	0.3	2
41	How professionals define medicines management: a preliminary qualitative investigation. International Journal of Pharmacy Practice, 2011, 10, R14-R14.	0.3	0
42	Pain relief in the elderly: are we doing enough?. International Journal of Pharmacy Practice, 2011, 10, R26-R26.	0.3	2
43	How much do recent users know about emergency hormonal contraception?. International Journal of Pharmacy Practice, 2011, 10, R56-R56.	0.3	0
44	Clinical medication review in general practice: what is the benefit of a second review?. International Journal of Pharmacy Practice, 2011, 10, R70-R70.	0.3	4
45	Clare wants the morning-after pill: what do practitioners think?. International Journal of Pharmacy Practice, 2011, 10, R71-R71.	0.3	1
46	â€œUser-testingâ€•as a method for testing the fitness-for-purpose of written medicine information. Patient Education and Counseling, 2011, 83, 404-410.	1.0	55
47	Can user testing of a clinical trial patient information sheet make it fit-for-purpose? - a randomized controlled trial. BMC Medicine, 2011, 9, 89.	2.3	70
48	Buyer beware? Does the information provided with herbal products available over the counter enable safe use?. BMC Medicine, 2011, 9, 94.	2.3	113
49	The stability of repeat prescriptions and the implications for instalment dispensing. International Journal of Pharmacy Practice, 2010, 12, R7-R12.	0.3	0
50	Self-management of heart failure: a place in practice?. International Journal of Pharmacy Practice, 2010, 13, R12-R18.	0.3	0
51	Evaluation of website medicines information content, in comparison with official patient information. International Journal of Pharmacy Practice, 2010, 14, 189-195.	0.3	2
52	How do patients use medicine information leaflets in the UK?. International Journal of Pharmacy Practice, 2010, 15, 209-218.	0.3	38
53	Addressing medication literacy: a pharmacy practice priority. International Journal of Pharmacy Practice, 2010, 17, 257-259.	0.3	25
54	Developing and testing a patient information booklet for thrombolysis used in acute stroke. International Journal of Pharmacy Practice, 2010, 18, 362-369.	0.3	14

#	Article	IF	Citations
55	Key Principles to Guide Development of Consumer Medicine Information—Content Analysis of Information Design Texts. Annals of Pharmacotherapy, 2009, 43, 700-706.	0.9	58
56	Performance-based readability testing of participant information for a Phase 3 IVF trial. Trials, 2009, 10, 79.	0.7	37
57	Addressing medication literacy: a pharmacy practice priority. International Journal of Pharmacy Practice, 2009, 17, 257-259.	0.3	2
58	Adequacy of Patient Information on Adverse Effects. Drug Safety, 2008, 31, 305-312.	1.4	37
59	Antipsychotic prescribing patterns in care homes and relationship with dementia. Psychiatric Bulletin, 2007, 31, 329-332.	0.3	20
60	The role and value of written information for patients about individual medicines: a systematic review. Health Expectations, 2007, 10, 286-298.	1.1	114
61	A systematic review of quantitative and qualitative research on the role and effectiveness of written information available to patients about individual medicines. Health Technology Assessment, 2007, 11, iii, 1-160.	1.3	221
62	Do themes in consumer medicines information literature reviews reflect those important to stakeholders?. Patient Education and Counseling, 2006, 64, 112-118.	1.0	12
63	Interpretation of Medication Pictograms by Adults in the UK. Annals of Pharmacotherapy, 2005, 39, 1227-1233.	0.9	71
64	We are the experts: people with asthma talk about their medicine information needs. Patient Education and Counseling, 2004, 53, 167-174.	1.0	109
65	Communicating risk of medication side effects: An empirical evaluation of EU recommended terminology. Psychology, Health and Medicine, 2003, 8, 251-263.	1.3	66
66	Provision of information about drug side-effects to patients. Lancet, The, 2002, 359, 853-854.	6.3	136
67	Patient information leaflets for medicines: using consumer testing to determine the most effective design. Patient Education and Counseling, 2001, 43, 147-159.	1.0	115
68	Randomised controlled trial of clinical medication review by a pharmacist of elderly patients receiving repeat prescriptions in general practice. BMJ: British Medical Journal, 2001, 323, 1340-1340.	2.4	249
69	Effects of a medicine review and education programme for older people in general practice. British Journal of Clinical Pharmacology, 2000, 50, 172-175.	1.1	98
70	Medicine Information Help Lines: A Survey of Hospital Pharmacy-Based Services in the UK and Their Conformity with Guidelines. Annals of Pharmacotherapy, 2000, 34, 106-111.	0.9	15
71	Medicines information—leaving blind people behind?. BMJ: British Medical Journal, 1997, 315, 268-268.	2.4	16
72	Effects of computer generated reminder charts on patients' compliance with drug regimens.. BMJ: British Medical Journal, 1993, 306, 1158-1161.	2.4	100